Rigel Pharmaceuticals (RIGL) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free RIGL Stock Alerts $1.48 -0.01 (-0.67%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRigel Pharmaceuticals (NASDAQ:RIGL) Upgraded by StockNews.com to "Buy"americanbankingnews.com - March 28 at 3:56 AMRigel Pharmaceuticals (NASDAQ:RIGL) Raised to "Buy" at StockNews.commarketbeat.com - March 27 at 11:16 PMRigel Pharmaceuticals (NASDAQ:RIGL) Shares Cross Above Two Hundred Day Moving Average of $1.17americanbankingnews.com - March 27 at 3:18 AMRigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to "Hold"americanbankingnews.com - March 19 at 2:28 AMRIGL Apr 2024 3.000 callfinance.yahoo.com - March 16 at 7:34 AMRigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officerfinanznachrichten.de - March 12 at 12:09 PMRigel Pharma Names Rojkjaer EVP, Chief Medical Officermarkets.businessinsider.com - March 12 at 12:09 PMRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officerprnewswire.com - March 12 at 8:05 AMRigel Pharmaceuticals (NASDAQ:RIGL) Upgraded at StockNews.commarketbeat.com - March 11 at 11:15 PMFY2024 Earnings Forecast for Rigel Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:RIGL)marketbeat.com - March 11 at 2:33 AMRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to Post Q1 2024 Earnings of ($0.01) Per Share, B. Riley Forecastsmarketbeat.com - March 8 at 6:19 AMRigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Yearfinance.yahoo.com - March 7 at 6:17 PMRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMCitigroup Raises Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target to $4.00marketbeat.com - March 7 at 10:33 AMB. Riley Weighs in on Rigel Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:RIGL)marketbeat.com - March 7 at 7:38 AMRigel Pharmaceuticals Inc.barrons.com - March 6 at 10:15 PMRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - March 6 at 5:14 PMRigel Pharmaceuticals: Q4 Earnings Insightsbenzinga.com - March 6 at 5:14 PMRigel Pharmaceuticals Inc. Q4 Earnings Summarymarkets.businessinsider.com - March 6 at 5:14 PMRigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39Mmsn.com - March 6 at 5:14 PMOwning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),finance.yahoo.com - March 6 at 5:14 PMQ4 2023 Rigel Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 6 at 5:14 PMRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - March 6 at 1:52 PMRigel Pharmaceuticals (NASDAQ:RIGL) Given New $3.00 Price Target at Cantor Fitzgeraldmarketbeat.com - March 6 at 12:42 PMRigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 6 at 9:45 AMQ4 2023 Rigel Pharmaceuticals Inc Earnings Call Transcriptgurufocus.com - March 6 at 12:03 AMRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023investorplace.com - March 5 at 9:01 PMRigel Pharmaceuticals (RIGL) to Release Earnings on Tuesdaymarketbeat.com - February 28 at 8:55 AMRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updateprnewswire.com - February 27 at 8:05 AMRigel Pharmaceuticals: Gavreto Deal Expands Growth Prospectsseekingalpha.com - February 26 at 6:28 PMBuy Rating for Rigel: Strategic Acquisitions and Market Positioning Fuel Revenue Growth Potentialmarkets.businessinsider.com - February 23 at 9:42 AMRIGL Mar 2024 1.500 putfinance.yahoo.com - February 23 at 12:52 AMRigel Pharmaceuticals Stock (NASDAQ:RIGL), Short Interest Reportbenzinga.com - February 22 at 7:52 PMRigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Marketmarkets.businessinsider.com - February 22 at 9:51 AMRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®finance.yahoo.com - February 22 at 9:51 AMRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®prnewswire.com - February 22 at 7:50 AMCan Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?finance.yahoo.com - February 19 at 12:51 PMRIGL Sep 2024 3.000 callca.finance.yahoo.com - February 18 at 5:30 PMRIGL Sep 2024 2.000 putca.finance.yahoo.com - February 18 at 5:30 PMRIGL Mar 2024 0.500 callfinance.yahoo.com - February 17 at 8:33 AMRIGL Jun 2024 3.000 callfinance.yahoo.com - February 16 at 10:53 PMRIGL Jun 2024 3.000 putfinance.yahoo.com - February 16 at 10:53 PMRigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Crosses Above 200-Day Moving Average of $1.13marketbeat.com - February 10 at 3:44 AMAssenagon Asset Management S.A. Cuts Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)marketbeat.com - February 2 at 5:48 AMRigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above 200-Day Moving Average of $1.14marketbeat.com - January 31 at 2:33 AMWhen Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?finance.yahoo.com - January 15 at 1:51 PMRigel Pharmaceuticals Expects 2023 Net Product Sales To Rise 36% - Quick Factsmarkets.businessinsider.com - January 8 at 1:09 PMRigel Pharmaceuticals, Inc.: Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)finanznachrichten.de - January 8 at 3:08 AMHC Wainwright Reaffirms Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)marketbeat.com - January 4 at 10:56 AMRigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Gliomafinance.yahoo.com - January 4 at 8:42 AM Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Major Elon Musk Crypto Leak Revealed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. RIGL Media Mentions By Week RIGL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼0.410.61▲Average Medical News Sentiment RIGL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼52▲RIGL Articles Average Week Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vanda Pharmaceuticals News Merrimack Pharmaceuticals News XOMA News G1 Therapeutics News Emergent BioSolutions News Avid Bioservices News Lexicon Pharmaceuticals News OPKO Health News Innoviva News FibroGen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.